Lojuxta
What Lojuxta is used for
Lojuxta is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low-density-lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH). Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Lojuxta
- Active substance
- lomitapide
- Disease area
- Hypercholesterolemia
- Medicine group
- Lipid modifying agents
- ATC code
- C10AX12
- Marketing authorisation holder
- Chiesi Farmaceutici SpA
- Authorised in the EU since
- 2013
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lojuxta used for?
Lojuxta is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low-density-lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH). Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded.
What is the active substance in Lojuxta?
Lojuxta contains lomitapide.
Who makes Lojuxta?
The EU marketing authorisation holder is Chiesi Farmaceutici SpA.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU